Abstract
A series of sixteen N-(trans)-3-phenylprop-2-en-1-yl (cinnamyl) derivatives of various aminoalkanols was synthesized and evaluated for anticonvulsant activity and neurotoxicity. In preliminary evaluation three standard tests in mice after intraperitoneal administration were used: maximal electroshock (MES), subcutaneous pentetrazol, and rotarod test. Fifteen compounds showed some protection in MES. Next step included evaluation in rats after oral administration. The most promising compound, (R,S)-2-{[(trans)-3-phenylprop-2-en-1-yl]amino}propan-1-ol hydrochloride (1a), was also tested in model of pilocarpine-induced status prevention, 6-Hz test, and in vitro neuroprotection evaluation. Additionally, for selected compounds experimental pKa values were determined as well as serotonin receptors (5-HT1A, 5-HT6, and 5- HT7) binding affinities were found. None of the tested compounds showed significant binding affinity to serotonin receptors. However, in vivo pharmacological results indicated that further modification of the structures might lead to discovering new potential anticonvulsants.
Keywords: Aminoalkanols, Anticonvulsant, Cinnamyl, Epilepsy, Maximal electroshock, Pentetrazol.
Letters in Drug Design & Discovery
Title:Synthesis and Anticonvulsant Activity of N-(trans)- 3-phenylprop-2-en-1-yl (Cinnamyl) Derivatives of Aminoalkanols
Volume: 11 Issue: 8
Author(s): Agnieszka Gunia-Krzyzak, Anna M. Waszkielewicz, Karolina Sloczynska, Magda Borczuch- Kostanska, Marek Cegla, Grzegorz Satala, Andrzej J. Bojarski and Henryk Marona
Affiliation:
Keywords: Aminoalkanols, Anticonvulsant, Cinnamyl, Epilepsy, Maximal electroshock, Pentetrazol.
Abstract: A series of sixteen N-(trans)-3-phenylprop-2-en-1-yl (cinnamyl) derivatives of various aminoalkanols was synthesized and evaluated for anticonvulsant activity and neurotoxicity. In preliminary evaluation three standard tests in mice after intraperitoneal administration were used: maximal electroshock (MES), subcutaneous pentetrazol, and rotarod test. Fifteen compounds showed some protection in MES. Next step included evaluation in rats after oral administration. The most promising compound, (R,S)-2-{[(trans)-3-phenylprop-2-en-1-yl]amino}propan-1-ol hydrochloride (1a), was also tested in model of pilocarpine-induced status prevention, 6-Hz test, and in vitro neuroprotection evaluation. Additionally, for selected compounds experimental pKa values were determined as well as serotonin receptors (5-HT1A, 5-HT6, and 5- HT7) binding affinities were found. None of the tested compounds showed significant binding affinity to serotonin receptors. However, in vivo pharmacological results indicated that further modification of the structures might lead to discovering new potential anticonvulsants.
Export Options
About this article
Cite this article as:
Gunia-Krzyzak Agnieszka, Waszkielewicz M. Anna, Sloczynska Karolina, Borczuch- Kostanska Magda, Cegla Marek, Satala Grzegorz, Bojarski J. Andrzej and Marona Henryk, Synthesis and Anticonvulsant Activity of N-(trans)- 3-phenylprop-2-en-1-yl (Cinnamyl) Derivatives of Aminoalkanols, Letters in Drug Design & Discovery 2014; 11 (8) . https://dx.doi.org/10.2174/1570180811666140423203639
DOI https://dx.doi.org/10.2174/1570180811666140423203639 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Infrared-Spectroscopy: A Non-Invasive Tool for Medical Diagnostics and Drug Analysis
Current Medicinal Chemistry The GABAA-BZR Complex as Target for the Development of Anxiolytic Drugs
Current Topics in Medicinal Chemistry Addressing Alzheimer’s Disease and Cognitive Loss through Autophagy
Current Neurovascular Research Editorial: [Hot Topic: Central Nervous System Drugs in the Treatment of Neurological Disorders]
Central Nervous System Agents in Medicinal Chemistry The Sustained Effects on Tear Volume of Pilocarpine Hydrochloride in Gelatin by Hydrogel Administered by An Implant-mediated Drug Delivery System
Current Drug Delivery Neurochemical Imbalance in Epilepsy from Animal Model to Human
Current Psychopharmacology GABA and Neuroactive Steroid Interactions in Glia: New Roles for Old Players?
Current Neuropharmacology Nutritional and Pharmacological Management of Childhood Epilepsy: Ketogenic Diets and Common AEDs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Animal Peptides Targeting Voltage-Activated Sodium Channels
Current Pharmaceutical Design The α2δ Subunit and Absence Epilepsy: Beyond Calcium Channels?
Current Neuropharmacology Developing Pharmacotherapies for Cannabis and Cocaine Use Disorders
Current Neuropharmacology Editorial [Abnormal Bleeding or Bruising Associated with Antiepileptic Treatment]
Current Drug Safety An Overview on Chemistry and Biological Importance of Pyrrolidinone
Current Organic Synthesis Ameliorative Potential of Glycyrrhiza glabra Extracts on Memory Impairments in Stress Triggered Rats
Current Traditional Medicine Integration of Internet of Things with Quantum Dots: A State-of-the-art of Medicine
Current Pharmaceutical Design Astrocyte-Neuron Interaction at Tripartite Synapses
Current Drug Targets Oral L-Carnitine: Metabolite Formation and Hemodialysis
Current Drug Metabolism